ReviewBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Section snippets
Identification of VEGF
In 1983, Senger et al. [9] reported the partial purification from the conditioned medium of a guinea-pig tumor cell line of “vascular permeability factor” (VPF), a protein that induced vascular leakage in the skin. Because VPF was not isolated and sequenced, this factor remained molecularly unknown at that time.
In 1989, our laboratory reported the isolation and NH2-terminal sequencing of VEGF, an endothelial cell-specific mitogen, from medium conditioned by bovine pituitary cells [10]. The
The VEGF isoforms
The human VEGF-A gene is organized in eight exons [14], [15]. Alternative exon splicing results in the generation of four main VEGF isoforms, having, respectively, 121, 165, 189, and 206 amino acids following signal sequence cleavage (VEGF121, VEGF165, VEGF189, and VEGF206) [12]. VEGF165 is the predominant isoform. Numerous less frequent splice variants have been also reported, including VEGF145, VEGF183 VEGF162, and VEGF165b (reviewed in [16]).
Alternative splicing regulates the bioavailability
VEGF receptors
There are two VEGF receptor tyrosine kinases (RTKs), Flt-1, known also as VEGFR-1 [27], [28] and KDR, Flk-1, or VEGFR-2 [29], [30], [31].
There is now agreement that VEGFR-2 is the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF. For a detailed review of the biological and signaling properties of the VEGF receptors, see [16].
Under some circumstances, VEGFR-1 may function as a “decoy” receptor that sequesters VEGF and prevents its interaction with VEGFR-2
Regulation of VEGF gene expression
Oxygen tension plays a major role in regulating the expression of a variety of genes, including VEGF, and HIF-1 is a key transcriptional regulator of hypoxic responses [40]. A link between the product of the von Hippel–Lindau (VHL) tumor suppressor gene and HIF-1-dependent responses has been established (for review sees [41]). The VHL gene is inactivated in patients with von Hippel–Lindau disease, an autosomal dominant neoplasia syndrome characterized by capillary hemangioblastomas in retina
Role of VEGF in tumor angiogenesis
In situ hybridization studies demonstrate VEGF mRNA expression in many human tumors. These include lung [50], breast [51], gastrointestinal tract [52], renal [53], and ovarian carcinomas [54]. However, the expression of VEGF appears to be variable, not only among different tumor types, but also within the same tumor (for reviews see [8], [16]). Renal cell carcinomas have a particularly high VEGF expression is renal cell carcinoma, in agreement with the notion that inactivating VHL mutations
Preclinical studies
In 1997, we reported the humanization of the murine anti-VEGF Mab A.4.6.1. [78]. Like its murine counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, but not mouse or rat VEGF. The binding epitope of bevacizumab has been defined by crystal structure analysis of a complex Fab ligand [79]. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal
Ongoing studies and perspectives
For the first-line treatment of metastatic colorectal cancer, the addition of bevacizumab to bolus IFL chemotherapy conferred a clinically meaningful and statistically significant benefit for all study endpoints, including overall survival, progression free survival, and response rate, and was associated with an acceptable side effect profile.
The improvement in survival attributable to bevacizumab is similar or greater than that observed in any Phase III trial for the treatment of colorectal
References (96)
- et al.
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
Biochem. Biophys. Res. Commun.
(1989) - et al.
Human vascular permeability factor. Isolation from U937 cells
J. Biol. Chem.
(1989) - et al.
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
J. Biol. Chem.
(1991) - et al.
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
J. Biol. Chem
(1992) - et al.
The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency
J. Biol. Chem.
(1996) - et al.
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
J. Biol. Chem.
(1998) - et al.
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Biochem. Biophys. Res. Commun.
(1992) - et al.
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
Cell
(1993) - et al.
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
J. Biol. Chem.
(1994) - et al.
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
Blood
(1996)
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
Cancer Cell
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
Cell
von Hippel–Lindau disease
Lancet
Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
J. Biol. Chem.
Oncogenic ras fails to restore an in vivo oncogenic phenotype in embryonic stem cells lacking VEGF
Biochem. Biophys. Res. Commun.
Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma
Eur. J. Cancer
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
Eur. J. Cancer
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
Cancer Cell
Tumor induction of VEGF promoter activity in stromal cells
Cell
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface
Structure
VEGF and the quest for tumour angiogenesis factors
Nat. Rev. Cancer
Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber
Am. J. Roentgenol.
Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparentchamber technique
J. Natl. Cancer Inst.
Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy
J. Natl. Cancer Inst.
Tumor angiogenesis: therapeutic implications
N. Engl. J. Med.
Regulators of angiogenesis
Annu. Rev. Physiol.
Vascular-specific growth factors and blood vessel formation
Nature
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Nat. Rev. Drug Discov.
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
Science
Vascular endothelial growth factor is a secreted angiogenic mitogen
Science
Vascular permeability factor, an endothelial cell mitogen related to PDGF
Science
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA
Mol. Endocrinol.
Vascular endothelial growth factor: basic science and clinical progress
Endocr. Rev.
The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
Mol. Biol. Cell
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Nature
VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction Pathway. requirement for Flk-1/KDR activation
J. Biol. Chem.
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
Proc. Natl. Acad. Sci. USA
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
J. Clin. Invest.
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
J. Clin. Oncol.
Blood vessels and nerves: common signals, pathways and diseases
Nat. Rev. Genet.
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family
Oncogene
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
Science
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
Proc. Natl. Acad. Sci. USA
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment
Nat. Med.
Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism
Nature
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
Nat. Med.
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1
Science
HIF hydroxylation and the mammalian oxygen-sensing pathway
J. Clin. Invest.
Cited by (840)
Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome
2024, Journal of Drug Delivery Science and TechnologyCholesterol crystals induce mechanical trauma, inflammation, and neo-vascularization in solid cancers as in atherosclerosis
2023, American Heart Journal Plus: Cardiology Research and PracticeSafety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma
2023, Clinics and Research in Hepatology and GastroenterologySafety and Efficacy of Temozolomide Combinations in Glioblastoma Patients; A Meta-Analysis
2024, Research Journal of Biotechnology